1. Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor Therapy
- Author
-
Youngran Park, Zheng Cheng Yu, Ayse Ayhan, Tian Li Wang, Raghavendra A. Shamanna, Ie Ming Shih, Sonia Franco, Akila N. Viswanathan, Michael M. Seidman, Vilhelm A. Bohr, M. Herman Chui, Marina A. Bellani, Stephanie Gaillard, Yohan Suryo Rahmanto, and Anthony K.L. Leung
- Subjects
0301 basic medicine ,Cancer Research ,DNA End-Joining Repair ,DNA Repair ,Cell Survival ,DNA repair ,DNA damage ,Poly ADP ribose polymerase ,Cell Cycle Proteins ,Mice, Transgenic ,Poly(ADP-ribose) Polymerase Inhibitors ,Models, Biological ,Radiation Tolerance ,Article ,Chromatin remodeling ,Olaparib ,Mice ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Cell Line, Tumor ,Animals ,Humans ,DNA Breaks, Double-Stranded ,Chromatin ,DNA-Binding Proteins ,Disease Models, Animal ,030104 developmental biology ,Oncology ,chemistry ,Drug Resistance, Neoplasm ,Gene Knockdown Techniques ,030220 oncology & carcinogenesis ,PARP inhibitor ,Cancer cell ,Cancer research ,DNA Damage ,Transcription Factors - Abstract
Purpose: Somatic inactivating mutations in ARID1A, a component of the SWI/SNF chromatin remodeling complex, are detected in various types of human malignancies. Loss of ARID1A compromises DNA damage repair. The induced DNA damage burden may increase reliance on PARP-dependent DNA repair of cancer cells to maintain genome integrity and render susceptibility to PARP inhibitor therapy. Experimental Design: Isogenic ARID1A−/− and wild-type cell lines were used for assessing DNA damage response, DNA compactness, and profiling global serine/threonine phosphoproteomic in vivo. A panel of inhibitors targeting DNA repair pathways was screened for a synergistic antitumor effect with irradiation in ARID1A−/− tumors. Results: ARID1A-deficient endometrial cells exhibit sustained levels in DNA damage response, a result further supported by in vivo phosphoproteomic analysis. Our results show that ARID1A is essential for establishing an open chromatin state upon DNA damage, a process required for recruitment of 53BP1 and RIF1, key mediators of non-homologous end-joining (NHEJ) machinery, to DNA lesions. The inability of ARID1A−/− cells to mount NHEJ repair results in a partial cytotoxic response to radiation. Small-molecule compound screens revealed that PARP inhibitors act synergistically with radiation to potentiate cytotoxicity in ARID1A−/− cells. Combination treatment with low-dose radiation and olaparib greatly improved antitumor efficacy, resulting in long-term remission in mice bearing ARID1A-deficient tumors. Conclusions: ARID1A-deficient cells acquire high sensitivity to PARP inhibition after exposure to exogenously induced DNA breaks such as ionizing radiation. Our findings suggest a novel biologically informed strategy for treating ARID1A-deficient malignancies.
- Published
- 2019
- Full Text
- View/download PDF